Hanmi Pharm: obesity drug sales and technology exports 'two-pronged'… earnings start to rebound
Predicted impact: Low
Q3 revenue up 4.2% and profit down; modest change already reported in the past 14 days.
Comments
No comments yet. Start the conversation.
Comments are people's own views. Nothing here is financial advice.